Artemis Medicare runs a network of tertiary and quaternary multi-specialty hospitals, anchored by a roughly 700-bed flagship in Gurugram that generates the highest average revenue per occupied bed in Delhi NCR at INR 85,690 in Q1 FY27. The company also operates a 300-bed Raipur hospital that opened its OPD on 9 July 2026, with theaters and cath lab live from 27 July, and is building a 650-bed South Delhi facility. Money is made from high-acuity procedures such as organ transplants, oncology and cardiology, plus an international patient franchise that contributed about 27% of Q1 revenue and is targeted to exceed 30% in Q2 FY27. The business quality is visible in margins: Q1 FY27 consolidated EBITDA was INR 61.82 crore, a 21.5% margin, up from 20.2% for FY26, and Gurugram standalone is guided to stay above 20% and move to 23-24% over two to three years. With roughly 700 beds in the flagship and a regional expansion pipeline, this is a scale game within a very high-acuity niche, not a commodity hospital operator.
Why do these economics persist? The barriers are clinical and relational rather than physical. Artemis has built a referral network through Daffodils and Artemis Lite hub-and-spoke centers, and its Gurugram campus is the largest hospital in the city by referrals, acting as the Haryana critical-care referral center. Its international patient base spans the Middle East, Africa, CIS, Canada and Nordic countries, with no single region accounting for more than 30% of international revenue, and management adds 2-3 new country fronts annually. Switching costs are high for complex procedures: a patient referred for heart or lung transplant is unlikely to change hospitals mid-cycle, and payer empanelment takes time, as seen in Raipur where insurance linkage is expected within 8-10 weeks of opening. The company also benefits from first-mover advantage in Raipur, where roughly 60% of local patients currently travel to Delhi or Mumbai for treatment, and it has hired two prominent local doctors as partners. Competitive pressure exists in Gurugram from standalone pediatric hospitals and in Raipur from Apollo and AIIMS, but Artemis's pricing power, evidenced by the highest ARPOB in NCR, and its 30% EBITDA flow-through on incremental revenue suggest the moat is underappreciated.
The inflection is capacity commissioning on a multi-year schedule. Raipur, with INR 120 crore capex, is now live and expected to run an INR 18-20 crore EBITDA loss in FY27 before breaking even in 15-18 months, implying breakeven around late 2027 or early 2028. The Gurugram flagship is adding Tower IV, 200-plus beds at a capex of INR 55 lakh per bed, to be operational in 18-22 months, with break-even in 8-10 months after opening and 50% occupancy targeted in the first six months. South Delhi VIMHANS, 650 beds with capex of roughly INR 350-360 crore for the first 450 beds, is planned for FY29. Eighteen to 24 months from now, around mid-2028, the operating bed count should be approximately 1,200-1,300: 700 in Gurugram, 200-plus in Tower IV, 300 in Raipur, possibly plus 100-125 beds from the Platinum Green Building FAR allowance without incremental construction cost. Raipur should be near or past break-even, Tower IV should be in its initial ramp, and Gurugram occupancy, guided to 70% by Q2 FY27, should be generating revenue growth of 15-17% with 23-24% standalone EBITDA margins.
Management's walk-talk is mixed but improving. The Raipur hospital was promised for Q1 FY27 and did open in July 2026, though earlier guidance had suggested commissioning by March 2026; the operating timeline slipped about one quarter. On margins, management delivered: FY26 EBITDA margin was 20.2% and Q1 FY27 came in at 21.5%, above the 20% floor it repeatedly committed to. However, the 70% Gurugram occupancy target has slipped repeatedly, from March 2026 to the end of FY27 or beginning of the next fiscal year, and the 2,000-bed capacity target moved from 2027-28 to 2029. On the latest call, management still committed to 70% occupancy by Q2 FY27 and reiterated 2,000 beds by 2029-30. Capital allocation is conservative for now: three-year capex of roughly INR 800 crore is expected to be funded by internal accruals of about INR 150 crore cash flow per year, existing debt of around INR 260 crore, and a potential INR 700 crore QIP expected within 6-8 months, with management stating it will minimize dilution and use debt before equity.
The quantified earnings path is clear. FY26 PAT was INR 104 crore, up 26.2%, and Q1 FY27 PAT was INR 31.44 crore, up 48.3% year on year, on consolidated revenue of INR 287.32 crore. With Gurugram growing at 15-17% and at least 30% of incremental revenue flowing to EBITDA, plus Raipur moving from an INR 18-20 crore loss to break-even and Tower IV adding margin-accretive revenue from roughly calendar 2028, consolidated EBITDA margin should improve beyond the current 21% and PAT growth should accelerate. For this to hold, Raipur must break even within 15-18 months, Tower IV must receive clearances on schedule, and international patient mix must not fall below the high-20s; the West Asian war already cut international flows 15-18% in March 2026 before recovering to 90% by May. The single most important falsifier is Raipur's occupancy ramp and break-even timeline: any further slippage there would delay the offset to Gurugram's margin expansion and undermine the 2,000-bed by 2029-30 thesis. If that holds, the business 18-24 months out will be a larger, higher-margin, multi-city quaternary network with a proven international franchise.
companyname: ARTEMISMED ticker: ARTEMISMED sector: Not classified Artemis Medicare Services Limited operates one of Delhi NCR's largest private tertiary and quaternary care hospitals. The flagship Artemis Hospital in Gurugram accounts for 95-97% of company revenue, with a campus currently operating roughly 700 beds across multiple towers. The clinical focus is high-complexity, high-acuity medicine: cardiology, oncology, neurosciences, orthopedics, organ transplantation (heart, lung, liver, bone...
Read the full report →capex, margin expansion, new product segment, geographic expansion
Bed capacity expansion guided to increase from 800 beds to 2,000 beds by 2029 driven by commissioning of Raipur and South Delhi facilities
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Artemis Medicare Services Limited and 4,900+ companies.
5-day free pass. No card required.